Not all hypotensive lipids act the same for individuals
January 15th 2004The advantages of the hypotensive lipids bimatoprost (Lumigan, Allergan), latanoprost (Xalatan, Pfizer), and travoprost (Travatan, Alcon) over timolol 0.5% (Timoptic, Merck) have been conclusively demonstrated in phase III clinical trials. As a class, these therapies have been shown to reduce IOP and to reduce fluctuations of the diurnal curve significantly. Yet, it is important to understand that despite these commonalities, differences also exist. It is only in understanding these differences, and matching them clinically to the individual profile of the patient, that we can choose the right drug at the right time.
Prostaglandin analogs help patients stick with regimen
January 15th 2004Baltimore-Patients prescribed latanoprost (Xalatan, Pfizer Ophthalmics) continue therapy significantly longer than their counterparts using other prostaglandin-type drugs, according to the results of a population-based, retrospective cohort study.
Autoantibody repertoires could be key in glaucoma research
January 15th 2004Mainz, Germany-Analysis of autoantibody repertoires using advanced pattern-matching algorithms, such as artificial neural networks, may be useful for diagnosis of glaucoma, said Franz H. Grus, MD, PhD. He is the group leader of the experimental ophthalmology unit ("Pathophysiology of the Eye"), department of ophthalmology, University of Mainz, Germany.
Soft punctal plugs ease dry eye after laser-vision correction
January 15th 2004Charleston, WV-Findings of a bilateral comparison study evaluating prophylactic punctal occlusion in patients undergoing laser- vision correction surgery indicate soft plugs (Soft Plug-SA, Oasis Medical) may provide greater comfort and for a longer duration than standard collagen plugs.
ACES, SEE meeting offers networking opportunities
January 15th 2004Between sessions, many networking opportunities are available to attendees. Delegates might enjoy one of two 2-hour bike tours of the island, visiting an archeological site, the Old Burnham Clam Factory, and the five-story mansion and former home of Bob Turley, the New York Yankees pitcher who threw the first 100-mph fastball.
Cole Eye Institute wins grant for imaging study
January 15th 2004Cleveland-The National Eye Institute has awarded Cleveland Clinic's Cole Eye Institute a $6 million grant to study advanced imaging for glaucoma (AIG). The Cole Eye Institute is organizing and coordinating a multicenter effort to develop and test advanced imaging technologies for the diagnosis and management of glaucoma.
Suction rings, software update allow for greater microkeratome control
January 1st 2004Advanced Medical Optics (AMO) has introduced three new suction rings and updated the software used in conjunction with the rings for its Amadeus microkeratome, features that increase the safety and versatility of the device, said physicians who are familiar with the upgraded product.
Various factors affect thickness of LASIK flaps
January 1st 2004Camarillo, CA-Analysis of the variables that can affect flap thickness in LASIK showed that thickness increased with greater microkeratome head plate depth, higher preoperative central corneal thickness, and smaller microkeratome suction ring diameter.
FDA approves first accommodative IOL
January 1st 2004Cataract surgeons who participated in the premarketing clinical trials for the model AT-45 accommodative IOL (Crystalens, eyeonics inc. [formerly C&C Vision]) are heralding that technology as an important advance. The lens affords patients clear uncorrected vision at near, intermediate, and distance. FDA approval for marketing of the lens was granted in November.
Femtosecond laser minimizes wavefront distortions
January 1st 2004Irvine, CA-Standard refraction and vision outcome measures were found to be excellent and comparable in eyes undergoing LASIK flap creation with the femtosecond laser (IntraLase FS, IntraLase Corp.) versus with a mechanical microkeratome, but flap construction with the femtosecond laser is associated with less change in ocular aberrations, according to Dan B. Tran, MD.
Zero compression head dramatically cuts risk of epithelial defect
January 1st 2004St. Louis-Epithelial defect risk associated with the Hansatome microkeratome (Bausch & Lomb) is significantly reduced by use of the zero compression head, according to the results of a retrospective study undertaken by Stephen A. Wexler, MD.
Microkeratome creates flaps for LASIK, LASEK procedures
January 1st 2004Barranquilla, Colombia-The Carriazo-Pendular microkeratome (Schwind Eye-Tech Solutions) is a highly versatile microkeratome that can be used with great safety to produce high-quality flaps for LASIK and perhaps even for LASEK procedures, said Cesar Carriazo, MD.
Epikeratome brings Epi-LASIK into hands of refractive surgeons
January 1st 2004The Centurion SES EpiEdge epikeratome (CIBA Vision) is a simple instru-ment to use that safely and reliably separates the epithelium from the stroma via mechanical forces to create an intact epithelial sheet in eyes undergoing Epi-LASIK, said Ioannis G. Pallikaris, MD, PhD, who invented Epi-LASIK and participated in the development of the epikeratome.
Supersonic waterjet able to cut LASIK flap with precision
January 1st 2004The HydroKeratome Waterjet System (Visijet Inc.), the first microkeratome that creates a LASIK flap using a continuous beam of ultra-high-pressure water instead of a metal blade, debuted at the 2003 annual meeting of the American Academy of Ophthalmology in Anaheim.
Alcon rings NYSE bell; anecortave trials begin
January 1st 2004New York-Tim Sear, Alcon Inc.'s chairman, president, and chief executive officer, rang the closing bell of the New York Stock Exchange at 4 p.m. Dec. 4 to celebrate the company's dramatic rise in stock price since its initial public offering.
FDA OKs duo of surgical devices from Nidek
January 1st 2004Fremont, CA-Nidek is introducing a new combination pachymeter and A-scan ultrasound unit, and what it is calling the industry's smallest green laser photocoagulator to the United States market. The products, which were launched at the American Academy of Ophthalmology annual meeting, both recently received FDA approval for commercial sales and marketing.
AMO, Alcon in dispute over phaco patents
January 1st 2004Santa Ana, CA-Advanced Medical Optics (AMO) is claiming, in a complaint filed in federal court, that Alcon's Infiniti and Series 20000 Legacy phacoemulsification systems infringe AMO patents for advanced fluidics technologies in the removal of cataracts.
ACES, SEE delegates merge for 'quality surgery' discussion
January 1st 2004Marco Island, FL-The American College of Eye Surgeons (ACES) andthe Society for Excellence in Eyecare (SEE), along with Ophthalmology Times,will join for the first time to present the SEE Island/Quality Surgery XVIIISeminar. The conference, to be held Feb. 28 to March 3 at the recently renovatedMarco Island Marriott Resort, will merge the best faculty and presentationsfrom the two ophthalmic societies.
Resource-based relative value scale dictates revenue stream
December 15th 2003Physicians need to have a firm understanding of the resource-based relative value scale (RBRVS) because this scale assigns valuation for billions of dollars worth of procedures and services that physicians provide annually. In addition, it directly has an impact on how the money will be apportioned.
Restoration of accommodation possible after cataract surgery
December 15th 2003Antwerp, Belgium-Patients who have received the CrystaLens AT-45 accommodating IOL (eyeonics, formerly C&C Vision, Aliso Viejo, CA) after cataract extraction achieve very good distance and intermediate vision as well as improvements in their near vision, according to Erik L. Mertens, MD, FEBO, director and ophthalmic surgeon at Antwerp Eye Center, Antwerp, Belgium.